Category - Developments

Developments

180 Life Sciences forms scientific advisory board

180 Life Sciences (NASDAQ:ATNF) formed a scientific advisory board (SAB) whose initial composition will include Prof. Raphael Mechoulam of Hebrew University, Israel; Dr. Kevin Tracey, of Hofstra/Northwell; Prof. Irene...

February 17, 2022

Developments

Revive gets FDA orphan drug nod for Bucillamine in IRI during liver transplant

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV; FRANKFURT:31R) received orphan drug designation from the FDA for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver transplantation. ...

February 15, 2022

Developments

Altamira Therapeutics completes enrollment in Phase 2 acute vertigo trial

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment in Part B of the Phase 2 TRAVERS clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The company expects to release top-line...

February 14, 2022

Developments

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics (NASDAQ:CYTO) expanded its existing marketing and distribution agreement with Wellesta Holding of Singapore for Altamira’s Bentrio nasal spray for personal protection against airborne viruses and...

February 9, 2022

Developments

Ondine treats first patients in Phase 2 nasal photodisinfection trial

Ondine Biomedical (LON:OBI) treated the first patients in its nasal photodisinfection exploratory Phase 2 trial to evaluate how effectively the treatment eradicates pathogens – Staphylococcus aureus – in the nose, and...

February 7, 2022

Developments

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics (NASDAQ:CYTO) entered into an agreement with Avernus Pharma of Dubai for the marketing and distribution of Bentrio, Altamira’s nasal spray for protection against airborne viruses and...

February 7, 2022

Developments

Altamira Therapeutics establishes OTC Consumer Health business unit

Altamira Therapeutics (NASDAQ:CYTO) established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio, its nasal spray for the protection against airborne viruses and allergens. OTC...

February 4, 2022

Developments

Aravive doses first patient in Phase 2 clear cell renal cell carcinoma trial

Aravive (NASDAQ:ARAV) dosed the first patient in the Phase 2 portion of a Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC). “Safety and preliminary activity data...

January 31, 2022

Developments

Talkiatry completes $37-million Series A financing

Closely-held Talkiatry, a provider of in-network psychiatric care, completed its $37-million Series A financing with an additional $17-million from Left Lane Capital. The latest round of funding comes just five months...

January 27, 2022

Developments

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Results of a non-clinical research study demonstrated that Hepion Pharmaceuticals’ (NASDAQ:HEPA) clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse...

January 26, 2022

Category - Developments

180 Life Sciences forms scientific advisory board

Revive gets FDA orphan drug nod for Bucillamine in IRI during liver transplant

Altamira Therapeutics completes enrollment in Phase 2 acute vertigo trial

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Ondine treats first patients in Phase 2 nasal photodisinfection trial

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics establishes OTC Consumer Health business unit

Aravive doses first patient in Phase 2 clear cell renal cell carcinoma trial

Talkiatry completes $37-million Series A financing

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

General

More